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Introduction
MicroRNAs (miRNAs) are small, single stranded and 
genomically encoded RNA molecules of approximately 
19 to 25 nucleotides in length that are found in all 
higher eukaryotes including mammals, fungi and plants. 
miRNA lin-4 was the first miRNA discovered in 1993, 
which regulates the developmental timing of larva by 
translation repression of the gene lin-14 in the nematode 
Caenorhabditis elegans (Lee et al., 1993). The discovery 
of miRNA was proven to be continued when a second 
miRNA, let-7, which was discovered in 2000 (Reinhart 
et al., 2000), repressed lin-41, lin-14, lin-28, lin-42, and 
daf-12 expression during alteration of the developing 
stage in C. elegans. Subsequently, let-7 was found to 
be homologous in other species, including humans, and 
revealed that the existence of miRNAs is quite common 
in eukaryotes, which is the one of the most exciting 
scientific breakthroughs in the last decade. Since then, 
thousands of non-coding RNAs have been studied and 
940 distinct miRNA molecules that exist in human 
genomes were identified and catalogued (Berezikov et 
al., 2005; Griffiths-Jones et al., 2008; Baumhoer et al., 
2012; Chaudhry and Lhakhang, 2012). Each miRNA 
is predicted to have hundreds of mRNA targets caused 
by the imperfect base pairing (Lim et al., 2005) to the 
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3’ untranslated region (UTR) of the target mRNAs 
and signalling the target for mRNA degradation. Thus, 
miRNAs have been identified as performing significant 
regulatory functions in various cellular, biological and 
pathological processes, including the differentiation, 
progression, apoptosis, and proliferation of cancer cells 
(Heneghan et al., 2010; Farooqi et al., 2014). These 
molecules characteristically moderate the translation and 
stability of mRNAs, including those genes that mediate 
processes in carcinogenesis, including the immune 
response, metabolism, inflammation, cell cycle control, 
viral replication, stem cell differentiation and human 
development (Farazi et al., 2013).
miRNAs, known as gene regulators, expressed more 
than 30% of protein-coding genes in the human genome at 
the post transcriptional stage and simultaneously targeted 
multiple genes in the initiation and progression of human 
malignancies (Croce, 2009). Recent studies also indicated 
the differences of miRNA expression profiling between 
tumour and normal cells that revealed that miRNAs are 
involved in the pathogenesis of all types of human cancer 
(Heneghan et al., 2010; Kobayashi et al., 2012; Su et al., 
2013). Furthermore, miRNAs play numerous roles as 
tumour suppressors due to the aberrant expression, which 
can lead to carcinogenesis by inhibiting the malignant 
potential, or react as an oncogene by triggering malignant 
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potential, or combined interaction in certain cases (Nana-
Sinkam and Croce, 2011; Kong et al., 2012). The various 
expressions of miRNA genes in cancer tissues may 
contribute to several factors including affecting the location 
of miRNA during the mapping of cancer-associated 
genomic regions, imperfect function of the miRNA, and 
epigenetic mechanisms that contribute to multifarious 
miRNA-mediated gene network dysregulation. In 
contrast, the unique expression and biological properties 
of different miRNAs in various cancer types can act as 
novel bio-markers from which a new strategy might be 
developed for microRNA gene therapy as a diagnostic 
and prognostic tool in cancer research (Stenvang et al., 
2008; Iorio and Croce, 2012a; Iorio et al., 2012; Corsini 
et al., 2012; Fink and Kishore Guda, 2013). In this review, 
we have reported the biogenesis of miRNAs, miRNAs 
roles in cancer and its potential as biomarkers for cancer 
diagnosis and prognosis including the regulation of key 
cancer-related pathways, such as cell cycle control and 
the miRNA dysregulation. Such depth information has 
the potential not only to identify the roles of microRNAs 
in cancer, but also to exploit microRNAs as potential 
biomarkers for cancer diagnosis and identify therapeutic 
target for new drug discovery. 
 
miRNA Biogenesis
More recently, many researchers have determined 
that microRNAs play an integral role as a sophisticated 
modulator and have demonstrated the evolutionary 
importance in the miRNA biogenesis process, function 
and degradation by a range of mechanisms involving 
numerous protein-protein and protein-RNA interactions 
(Kim et al., 2009; Krol et al., 2010). Hence, understanding 
the miRNA biogenesis pathway is crucial due to the 
multiple links between human diseases, especially cancers, 
and the irregular expression of miRNAs or deficiency in 
miRNA biogenesis (Iorio and Croce, 2012a). Most miRNA 
genes are located in intergenic regions, which have been 
predicted from annotating regions in the genome data 
software, and can be found between the exonic and 
intronic regions in either sense or antisense alignments 
(Ruby et al., 2007). 
In a canonical pathway, miRNA regulation begins with 
RNA polymerase II-dependent transcription of miRNA 
molecules in a nucleus by generating long primary miRNA 
transcripts (pri-miRNA) that fold into a hairpin structure 
(Carthew and Sontheimer, 2009; Kim et al., 2009). Pri-
miRNAs with 5’7 methyl-guanosine (m7G) capped and 
3’polyadenylated are cleaved by the Microprocessor 
Complex, which is attained through catalytic cleavage of 
the double-stranded stem by the RNase III endonuclease 
Drosha (van Kouwenhove et al., 2011), while the hairpin 
is correctly positioned by co-factor DGCR8 in humans 
(Di George syndrome Critical Region 8, known as Pasha 
in D. melanogaster and C. elegans) (Melo and Esteller, 
2011a; Melo and Esteller, 2011b). They regulate each 
other through the response mechanism while DGCR8/
Pasha stabilizes Drosha by interacting with its C-terminal 
domain and endonuclease cleaves two hairpin structures 
in the 5’UTR and coding region of Dgcr8 mRNA, 
consequently resulting in its degradation (Han et al., 2009; 
Martinez and Gregory, 2013). 
The product from Drosha cleavage is approximately 70 
nucleotide (nt) stretches of stem-loop-forming precursor 
miRNA transcripts (pre-miRNA). Pre-miRNAs, which 
form short RNA hairpins bearing a 2-nt 3’overhang, are 
bounded with the nuclear export factor exportin-5 (XPO5 
complex protein in with Ran protein) and then shuttled 
to the cytoplasm along with GTP hydrolysis, known as 
nucleocytoplasmic transport pathways (Melo and Esteller, 
2011b). Once in the cytoplasm, (dsRNA)-specific RNase 
III endonuclease enzyme, termed Dicer1, together with 
its catalytic partner human immunodeficiency virus 
transactivating response RNA-binding protein (TRBP), 
removes the terminal loop of the pre-miRNA to further 
process it to an ~20-22 nt mature miRNA duplex (Inui 
et al., 2010).
The miRNA duplex  now consis ts  of  two 
5’phosphorylated sequence strands with 3’overhangs 
named miRNA (mature miRNA guide strand) and 
miRNA* (complementary passenger strand), and recently 
named as (miR-3p/*miR-5p) (Iorio and Croce, 2012b). 
The mature miRNAs guide strand, which is generally 
selected according to its thermodynamic properties, is then 
loaded into a multi-complex; the RNA-induced silencing 
complex (RISC) comprising argonaute proteins (AGO2) 
in which the miRNAs function as post-transcriptional 
regulators of gene expression through direct base 
pairing with the target mRNAs (miRISC) (Garzon et al., 
2010). The miRNAs specific binding to complementary 
sequences of mRNAs may either RISC induces mRNA 
degradation (perfect pairings) or the translation into 
protein is blocked (imperfect miRNA-mRNA target 
pairing) was defined by Watson-Crick base pairing 
between positions 2 to 8 from the 5’miRNA (also known 
as the seed) with the 3’untranslated region (UTR) of 
their target mRNAs (Ghildiyal and Zamore, 2009; Bartel, 
2009). The formed miRNA with RISC are then transported 
back into the nucleus to exert its biological effect since 
a single miRNA is capable of targeting hundreds of 
mRNAs, which highlights the impact of gene regulation 
system in cellular functions (Taby and Issa, 2010). The 
complementary passenger strand (miRNA*), which was 
initially thought to be degraded and known as a non-
functional bioproduct of miRNA biogenesis (Gregory et 
al., 2005), has recently become an interesting revelation 
Figure 1. miRNA Biogenesis Pathway
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for researchers inasmuch as new findings suggest that it 
can be specified as a functional strand. Reviews of the 
evidence that miRNA* plays a significant role in cellular 
function have reported on miRNA* activity in human 
diseases, especially cancer (Bhayani et al., 2012; Iorio 
and Croce, 2012b). 
In a contradictory way, a few pre-miRNAs are 
processed directly from short introns (mirtrons) bypassing 
the Drosha-DGCR8 step in the biogenesis pathway. 
Through the dicer-independent mechanism, the miRNA 
was cleaved by AGO2 to form a mature miRNA, while 
some of the miRNAs bind to the 5’-UTR of the target 
mRNA and lead to translational activation. Then, the 
complementarity between miRNA and the mRNA target 
is facilitated by miRISC directed cleavage of the mRNA 
target but the low complementarity of miRNA-mediated 
regulation is carried out by translational repression. 
Therefore, pre- and/or post initiation of translation may 
occur by leading to gene silencing. The target mRNAs 
can also be stored in processing bodies or cytoplasmic 
and the reverse mechanism may occur by re-entry into the 
polysomes for translation. Finally, the RISC-independent 
decoy activity, has recently reported that miRNAs can 
bind to ribonucleoproteins in a seed sequence and a 
RISC-independent manner and then interfere with their 
RNA binding functions (Beitzinger and Meister, 2010; 
Parasramka et al., 2012). Furthermore, the suppression of 
the key regulators in miRNA biogenesis machinery, such 
as Drosha, DGCR8, DICER1, TRBP and XPO5, may be 
dysfunctional or dysregulated in cancer and may promote 
cellular transformation by enhancing tumourigenesis 
(Melo et al., 2010; Melo and Esteller, 2011b). Therefore, 
different vigorous activity and the role of noncoding RNAs 
in the biogenesis process is of significant importance, 
especially in cancer biology studies, which may contribute 
to the development and stimulate various cancerous cells.
MicroRNAs as Oncogenes and Tumour 
Suppressors
MicroRNAs can react as a ‘tumour suppressor 
gene’, which is a gene that protects a cell from one 
step on the path to cancer; for example, when lost in 
tumour, or usually downregulates the expression of an 
‘oncogene’, which is a gene that has the potential to 
cause cancer. Moreover, in some cases same miRNA 
(such as miR-205) will acts either as an oncogene via 
facilitating tumor initiation and proliferation, or as a tumor 
suppressor through inhibiting proliferation and invasion 
in different types of cancers (Orang et al., 2014). The 
loss of functional miRNAs in the biogenesis pathway by 
mutations, deletions, promoter methylation, inactivation 
or any abnormalities may lead to an irregular expression 
of the target oncogene, which can form tumorous cells 
(Wong et al., 2011). More loss of miRNA expression 
has been found in various cancerous cells compared to 
normal cells; the involvement of miRNAs in human 
cancer, known as oncogenic miRNAs/‘oncomir’, was first 
proven in 2002 by Dr Croce’s group; miR-15a-miR-16-1 
expression was frequently deleted or downregulated in 
patients with chronic lymphocytic leukaemia (CLL) at 
chromosome 13q14 (Calin et al., 2008). Subsequently, 
other findings, such as the loss of the mir-29b-1-mir-29a 
(Garzon et al., 2009) in leukaemia patients resulted in 
the upregulation of target oncoproteins, such as B-cell 
lymphoma protein-2 (BCL-2), myeloid cell leukaemia 
sequence 1 (BCL-2-related) (MCL1), TCL1, CDK6 
and DNA methyltransferase 3α (DNMT3a) (Garzon et 
al., 2010). In addition, the overexpression of miRNAs, 
which downregulates the tumour suppressor genes, may 
also induce cell tumour proliferation, angiogenesis, and 
invasion by preventing apoptosis and increasing genetic 
instability. For example, the amplification expression 
of mir-17, mir-21 and mir-155 relatively cause tumour 
initiation and progression by inhibiting the expression 
of tumour suppressor genes, such as phosphatase and 
tensin homologue (PTEN), and programmed cell death 
4 (PDCD4) (Meng et al., 2007; Petrocca et al., 2008; 
Frankel et al., 2008). In contrast, p53, also known 
as tumour protein 53, and is a tumour protein that in 
humans is encoded by the TP53 gene (McBride et al., 
1986), is the most important and well-studied cancer 
gene that regulates the cell cycle involved in preventing 
cancer. Fundamentally, the action of p53 is to induce 
the expression of miRNAs, best described by the miR-
34 family, which represses genes that can promote 
proliferation and apoptosis (He et al., 2007). Additional 
discoveries indicate that p53-regulated miRNAs, such as 
miR-192, miR-194, miR-215 and miR-605, can target 
MDM2, which is a negative regulator of p53 (Deng and 
Sui, 2013). Furthermore, miR-107 and miR-200 inhibit 
angiogenesis and epithelial-to-mesenchymal transition 
(Chang et al., 2011), and other miRNAs - miR-15/16 and 
miR-192/194/215 families, miR-145 and miR-107 - are 
directly induced by p53, and provides a pathway for 
general insights of the miRNA-mediated control of gene 
expression and the potential therapeutic opportunities for 
targeting the p53 network (Lujambio and Lowe, 2012; 
Krell et al., 2013). Besides that, Suzuki and colleagues 
(2009) contended that p53 can affect miRNA biogenesis 
by regulating the process of precursor miRNAs when 
binding to large DROSHA complex. Supporting findings 
showed that the mutant p53 binds to inactivate p63, which 
may reduce the expression of DICER1 and cancer relevant 
miRNAs (Su et al., 2010). Consequently, the p53 network 
is a typical example that miRNAs are related to cancer-
relevant pathways at multiple stages and are unpredictable. 
Thus, a better perception of miRNA biology will help to 
decipher the role and function of other important cancer 
genes.
miRNAs in Cell cycle Regulation
The majority of the tumour-suppressor or oncogenic 
miRNAs associated with targeting the cell cycle regulators 
have been described as a tumour-related and oncogenic 
function of the miRNA alteration in cancerous cells in 
most of the related miRNAs studies. Furthermore, Wan et 
al. (2012) recently reported that most of the up-regulated 
genes were related to cell cycling. The cell cycle dissection 
is regulated by numerous molecular pathways and specific 
access points (Figure 2). Generally in the process of 
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DNA synthesis, transcription of genes are requisite for 
DNA duplication throughout the period of S phase and 
chromosome division during the period of M phase 
known as mitosis (Malumbres and Barbacid, 2001). In 
the most of mitogenic pathways, transcriptional induction 
of D-type cyclins and activation of cyclin-dependent 
kinases (CDKs) such as CDK4/CDK6 used to be occurred 
and resulted in an inactivation of retinoblastoma protein 
(pRB), leading to the inhibition of E2F transcription of 
cell cycle targeted genes (Bueno and Malumbres, 2011). 
The first oncogenic miRNA gene, mir-17-92, and miR-
106b-25 clusters up regulation, lead to the activation of 
Cyclin-CDK1 complexes regulators (control of cell cycle) 
and cell cycle progression by targeting p21Waf/Cip1 
(cyclin-dependent kinase inhibitor 1 or CDK-interacting 
protein 1) and inhibit the G1/S phase switch (Fornari et 
al., 2008). Similarly, up regulation of mir-17-92 and miR-
21 by targeting PTEN (phosphatase and tensin homolog 
protein act as a tumour suppressor gene in the regulation 
of the cell cycle) and inhibit expression of the transcription 
factor E2F1, whereby miR-221/222 up regulation are 
targeting p27Kip1 (a cell-cycle regulatory protein that 
interacts with cyclin-CDK2/-CDK4) and inhibiting cell 
cycle progression at G1, promote cellular proliferation 
and are capable of up regulating the components of the 
apoptotic signalling pathway and transforming to cancer 
cells resistant or susceptible to extrinsic factors at the 
same checkpoint (Petrocca et al., 2008). Conversely, 
oncogenic miRNA; miR-15a, miR-16-1 cluster and related 
miR-15b, miR-16-2 cluster in CLL patients regulated 
by E2F1 (a critical downstream target of the pRB) often 
inactivated in human tumours resulting in dysregulation 
of E2F activity which have been reported that reduces the 
levels of cyclin D1, cyclin D3, cyclin E1, and CDK6 was 
triggers an accumulation of multiple cell cycle-promoting 
genes and was predicted that both miRNAs contribute 
to apoptosis by decreasing the levels of the apoptotic 
inhibitor Bcl-2 at G1/S phase (Ofir et al., 2011). Recent 
findings determine that knockdown of microRNA-34a 
decreased the rate of apoptosis caused by PRIMA-1 
which is a small molecule that restores tumour suppressor 
function to mutant p53 to induced apoptosis in the cell 
cycle (Duan et al., 2010). Therefore, it can be suggested 
that microRNA-34a is one of the important components of 
PRIMA-1-induced apoptotic network in the cancer cells 
harbouring mutant p53. In addition, the latest findings 
focused on differentially expressed miRNAs (DEmiRs) 
involvement in the cell cycle where the specific functions 
of the p53 pathway might be affected by DEmiRs in 
cell cycle arrest and apoptosis. They summarised that a 
group of 26 DEmiRs were found (23 up-regulated and 
3 down-regulated) including hsa-miR-21-5p, hsa-miR-
148a-5p, hsa-miR-181a-5p, hsa-miR-323-3p, and hsa-
miR-487b-3p, as greatly expressed, and hsa-miR-19a-5p 
and hsa-miR-25-5p, as down-regulated DEmiRs and 
the computational analysis revealed that these DEmiRs 
might only regulate four annotated pathways which are 
cell proliferation, cell cycle, p53 and TGF-beta/BMP. 
Moreover, they concluded that, hsa-miR-21-5p, hsa-
miR-135b-5p and hsa-miR-181c-5p might be regulating 
cell proliferation and affecting the PTEN by negatively 
regulating Akt/PKB and Notch and/or Wnt signaling 
pathway in cell cycle which can be associated with 
carcinogenesis (Sanchez-Diaz et al., 2013). Apart from 
that, miR-369-3 or let-7, related family members activate 
the translation in inactive cell lines but suppress the 
translation in proliferating cells (Vasudevan et al., 2007) 
which indicates that miRNAs have the possibility in up 
regulation or down regulation of the translation depending 
on the cell cycle stage of the cells. All the findings about 
miRNAs in cell cycle regulation, including modulation in 
cell-cycle entry and progression, control of miRNAs in 
cell cycle of tissue homeostasis, and proliferative diseases, 
have been given emphasis for intense research in the 
upcoming years in order to understand the connections 
between miRNAs and the cell division cycle.
miRNA Dysregulation
miRNA dysregulation is caused by several mechanisms 
in human cancer including DNA copy number amplification 
or deletion (Calin and Croce, 2006), genetic mutations, 
polymorphisms (SNPs), epigenetic mechanism (Lujambio 
et al., 2008) and deficiency of the key regulators in the 
miRNA biogenesis pathway (Iorio and Croce, 2012a). 
miRNAs often exist in particular genomic regions 
including the minimal region of the loss of heterozygosity, 
which may harbour tumour suppressor genes; a minimal 
region of amplification, which might consist of oncogenes 
known as fragile sites prone to modification in cancer. 
Early in 2004, Calin reported that around 50% of miRNAs 
are located at fragile sites and cancer susceptibility loci, 
which are preferred for mature chromatid exchange, 
translocation, deletion, amplification of plasmid DNA 
and insertion of tumour associated viruses (Calin and 
Croce, 2006; Croce et al., 2010; Croce, 2013). The 
dysregulation of miRNAs expression can be attributable 
to react critically in tumourigenesis either by inhibiting 
tumour suppressor genes or activating oncogenes 
incongruously, thereby contributing to oncogenesis and 
cancer progression. Previous findings proved that miRNA 
expression is mutually related to miRNA copy number and 
tightly overlap with the miRNA expression; for example, 
Figure 2. The MiRNA in Cell Cycle Regulation by 
Numerous Molecular Pathways and Specific Access 
Points
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miR-15a/16 cluster of CLL, located in instable genomic 
regions embedded into 13q14, which often harbour 13q14 
deletions, showed a decreased expression of miR-15a 
and miR-16. The deletion of 5q33 region contributed to 
decrease the levels of miR-143 and miR-145 expression 
in lung cancer. The alteration in miRNA seed sequence 
caused by mutation has the potential to remove target 
repression by tumour-suppressive miRNAs or allowing 
the modification of target selection, which may lead to 
oncogenesis. Moreover, normally occurring sequence 
variations, such as SNPs, also influenced miRNA targeting 
in cancer-related pathways (Wynendaele et al., 2010). 
These findings suggested that the location of miRNAs in a 
genomic region responsible for the alterations of miRNAs 
in a specific type of cancer might participate in the cause 
of the malignancy in human.
Other recent findings, which indicated that 
epigenetic aberrations affect miRNA expression by 
DNA hypermethylation of the tumour suppressor genes, 
extensive genomic DNA hypomethylation and the 
alteration of histone modification patterns, explained 
the dysregulation of miRNA in cancer (Lopez-Serra 
and Esteller, 2011). From an extensive analysis of 
genomic sequences, large proportions of miRNA loci are 
associated with CpG islands suggesting that miRNAs 
can represent candidate targets of the DNA methylation 
machinery. For example, miR-21 and miR-203, which 
were implanted in a region with CpG islands, equally 
decreased miR-124a expression, which was attributed 
to DNA hypermethylation in colon, breast, and lung 
carcinomas (Lujambio et al., 2008). Other studies have 
experimentally proven that potentially oncogenic miRNAs 
can be upregulated by DNA hypomethylation (Iorio et al., 
2005), such as upregulation of hypermethylated tumour 
suppressing miRNAs by 5-aza-20deoxycytidine treatment 
in the case of as miR-127, miR-9-1 and miR-34b/c cluster 
(Toyota et al., 2008). Histone acetylation also represents 
a similar mechanism of epigenetic alteration in cancer 
by reducing the level of acetylated histones, which can 
diminish the expression of anti-oncogenic miRNAs by 
utilising histone deacetylase inhibitors; alteration of the 
miRNA levels have been observed during the treatment, 
which was among the evidence defined by Saito and 
colleagues (2006). Furthermore, they elaborated that the 
inhibition of DNA methylation and histone deacetylation 
only stimulates the expression of miR-127 in cancer cells 
and that the miR-127 and miR-124a genes affects the 
expression of two oncogenic proteins BCL6 and CDK6. 
Subsequently, restoration of miR-29 expression in lung 
cancer cells downregulates the repression of tumour 
suppressor genes silenced by CpG island methylation 
(Fabbri et al., 2007) and miR-101 targets the histone 
methyltransferase EZH2, which focuses more on 
epigenetic silencing of the target genes and regulates 
the survival and metastasis of cancer cells (Varambally 
et al., 2008). The latest findings reviewed by Iliopoulos 
et al. (2010) indicated that SUZ12 is a component of 
the polycomb repressor complex 2(PRC2) with EZH2 
being the catalytic subunit targeted by the miR-200 
family, which seems to be significantly important in the 
formation of cancer stem cells where the loss of miR-200 
increases SUZ12 expression, SUZ12 binding, H3-K27 
trimethylation, and Polycomb-mediated repression of the 
E-cadherin gene. The epigenetic changes conjoined by 
genetic inactivation due to mutation or deletion might be 
a potential mechanism that is partially involved in miRNA 
dysregulation of cancer cells.
The inhibition of miRNA biogenesis by suppression of 
miRNAs processing machinery key regulators including 
Drosha, DGCR8, DICER1, TRBP and XPO5 leads to 
severe developmental defects, and promotes cellular 
transformation and tumourigenesis (Kumar et al., 2009; 
Melo et al., 2010). However, the mechanism remains 
unclear and ongoing research in this particular area 
suggested that miRNAs might have an intrinsic function in 
tumour suppression and that its downregulation eventually 
accelerates oncogenesis. Mutations that inactivate XPO5, 
known as nuclear export receptors, function in pre-
miRNAs transit from the nucleus into the cytoplasm in 
human tumours, which leads to precursor accumulation 
in the nucleus and lower levels of mature miRNAs. 
The inefficient nuclear export and the presence of an 
inactivating mutation in the exportin-5 gene prevent the 
formation of a functional XPO5/RAN/GTP/pre-miRNA 
complex in the miRNA biogenesis pathway. Melo and 
friends also reported that frameshift mutations in the 
XPO5 gene in two MSI+ cell lines and primary tumours 
that have been found in exon 32 alter and abbreviate the 
protein sequence and prevent XPO5 from associating 
with its pre-miRNA cargo and exiting the nucleus (Melo 
et al., 2010). In XPO5 heterozygous mutant cells, less 
pre-miRNA was available to process in the cytoplasmic 
machinery, resulting in degradation of the mature miRNA 
and promoting tumourigenicity (Melo and Esteller, 2011a). 
In addition, Kumar and colleagues (2009) stated that 27% 
of different tumours consist of hemizygous deletion of the 
gene that encodes DICER1. Global knockdown of mature 
miRNA production by the depletion of any of the miRNA 
processing regulators, such as Drosha, RNase, DCGR8 or 
Dicer, has been shown to promote oncogenesis (Jansson 
and Lund, 2012). Apparently DICER1 and TARBP is a 
haploinsufficient tumour suppressor, requiring partial 
deletion for its associated tumourigenesis phenotype; for 
example, the mutations of TARBP that damage the miRNA 
processor and mutations of XPO5 that trap miRNA 
transcripts in the nucleus, correlate with carcinomas 
characterised by microsatellite instability (Melo et al., 
2009; Melo et al., 2010). Moreover, some studies showed 
that TARBP is mutated in colon and gastric cancers, which 
correlates with DICER1 destabilization in the cell line and 
xenografts with TARBP mutations, thereby reintroduction 
of wild-type TARBP2/DICER1 slowed tumour growth 
(Melo et al., 2009). The tumour suppressor p53 is a key 
regulator of miRNAs with anti-oncogenic roles capable 
of modulating miRNA expression by the transcription 
factor and affecting miRNA biogenesis in a transcription-
independent manner. For example, p53 has been described 
as modulating miRNA processing through interaction 
with the Drosha processing complex (Suzuki et al., 2009), 
while other members of the miR-103/107 family have 
been shown to target Dicer by reducing the expression 
of miRNA levels (Martello et al., 2010) in cancer cells. 
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A few of the latest discoveries of dysregulation miRNAs 
in biogenesis machinery have been published; for 
example, miRNA bindings with competing endogenous 
RNAs (ceRNAs) network may furnish the chance of an 
additional level of post-transcriptional regulation and 
reassessment of the existing regulatory pathways involved 
in cancer initiation and progression microRNAs (Su et 
al., 2013). The mechanisms resulted in alteration of the 
expression of UTRs in transcripts and influence miRNA 
response elements (MRE) levels. Alteration in the MREs 
of ceRNAs affect the capability of the mRNA transcript 
to attach miRNAs where the disturbed ceRNA network 
may contribute to diseases and cancers (Salmena et al., 
2011; Karreth et al., 2011). Subsequently, in another latest 
finding, Shen et al. (2013) proved that the epidermal 
growth factor receptor (EGFR) directly interacts with 
argonaute2 (AGO2), a crucial component of the RNA-
induced silencing complex (RISC) and prevents cell 
transformation of specific tumour suppressive miRNAs 
under hypoxic conditions. Hypoxic stress induces the 
endocytic trafficking of EGFR into cytoplasm, where 
EGFR interacts with AGO2 to reduce the binding of 
Dicer to AGO2 by phosphorylating AGO2-Y393, which 
results in weakening the process of pre-miRNAs to 
mature miRNAs (Nishida et al., 2013). Therefore, the 
perception of mechanisms behind miRNAs dysregulation 
in human cancer and noteworthy functions might render 
new insights for improving the classification, prognosis 
prediction and in the treatment of cancer. 
MicroRNAs as Potential Biomarkers for 
Cancer Diagnosis and Prognosis 
The accumulated studies and analysis on miRNA 
expression levels in tumourigenesis have determined that 
miRNAs play a huge role as prognostic and/or diagnostic 
markers and promising candidates to distinguish different 
tumour types as well as for predicting the clinical behaviour. 
The most significant up-to-date findings of miRNAs in 
cancer concentrate more on the potential of cancer-related 
miRNAs (oncomiRs) as biomarkers for diagnosis (Lin et 
al., 2014), prognosis and therapy. Furthermore, therapeutic 
approaches involving the re-introduction of miRNAs lost 
in cancer or inhibition of oncogenic miRNAs are rapidly 
being developed. Additionally, the antisense technology 
based on antagomiRs which can inhibit the activity of 
oncogenic miRNAs, is the major method used to reduce 
unwanted miRNA expression in tumor cells (Mollaie et 
al., 2013). Recently Xu et al. (2012) reported that multi-
target anti-microRNA antisense oligonucleotide (MTg-
AMOs) can specifically inhibit the expression of multiple 
miRNAs, and effectively antagonize proliferation and 
migration of gastric cancer cells promoted by oncomirs. 
They also suggested that in future, MTg-AMOs can not 
only be used as an ideal choice of clinical anti-tumor 
drugs, but can also serve as an important tool for exploring 
the functions of miRNAs in a number of human tumor 
types. Also, miRNAs are becoming promising targets for 
new drug developments in that advanced research could 
correct the miRNAs regulation by the loss of function or 
gain of function of miRNAs, which would influence the 
initiation and progression of cancer (Zhao et al., 2014). 
Besides that, regulating the gene network could change 
the behaviour of the cancer cells. 
Several diagnostic tools have been implemented for 
the detection and quantification of microRNA expression 
levels, such as northern blotting, semiquantitative in situ 
hybridization, quantitative real-time PCR, fluorescence-
labelled bead technology, and array hybridization with 
various probe sets and alternative protocols and methods 
for microRNA profiling of FFPE specimens, which are 
based on real-time PCR or microarray-hybridization 
(Lawrie, 2008; Streichert et al., 2011; Khan et al., 2011; 
Streichert et al., 2012; Josephine Wu et al., 2013). For 
example, the basic MiRNA profiling that identified that 
the induction of many miRNAs was coincident with the 
different stages of differentiation was proved by Volinia 
and colleagues (Volinia et al., 2006) using hierarchical 
clustering analysis of 540 samples including 363 from 
six of the most frequent solid tumour types (breast, colon, 
lung, pancreas, stomach, and prostate). Furthermore, 177 
normal controls showed that a unique miRNA signature 
enabled the tumour samples to be grouped on the basis 
of their tissue of origin. Again, recently, they have 
experimentally proven the mechanism, especially in breast 
cancer by using deep sequencing of microRNA, which 
also highlighted the prognostic role of these small RNAs 
in a large set of samples (Croce et al., 2012; Volinia et 
al., 2012). Nevertheless, each of the approaches has its 
own specific advantages and disadvantages. Recently, 
the findings of miRNAs in body fluids, such as serum, 
urine and colostrum (Hanke et al., 2010; Link et al., 
2010) have strengthened investigations into the use of 
miRNAs as non-invasive biomarkers of disease and a 
therapeutic response in a range of cancers including lung 
cancer, ovarian cancer, colorectal cancer, renal cancer, 
glioblastoma, prostate cancer and breast cancer (Cortez et 
al., 2012). In recent times, Lin et al. (2014) characterized 
miRNAs expression profiles in cervical cancer of Uygur 
women to identify the biomarkers for early diagnosis. 
Their data showed that the expression of Cox-2 protein 
level was significantly increased in cervical cancer. The 
levels of miR-101 and Cox-2 were negatively correlated 
in cervical cancer of Uyghur women, which may serve 
as biomarkers of diagnosis markers for cervical cancer 
in Uyghur women which provide direct experimental 
evidence for the roles of miRNA in diagnosis of cancer. 
Meanwhile, blood based tests for screening purposes or 
disease monitoring would be more suitable as they are 
minimally invasive, relatively have low cost and can be 
repeated as well (Ramshankar and Krishnamurthy, 2013). 
Because of this, Ramshankar and Krishnamurthy (2013) 
reported that the circulating miRNAs present in both serum 
and plasma as attractive candidates to be used as cancer 
biomarkers and could serve as non- invasive biomarkers 
for early detection and diagnosis of lung cancer.
Evidently, several studies have demonstrated that 
miRNAs can be responsible for drug resistance because 
of the significance of miRNAs in cancer management by 
modifying the expression also targeted as a therapeutic 
strategy. Accordingly, the delivery modality of miRNAs 
or anti-miRNAs can be used in therapeutics, either 
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individually or in combination with other treatments, 
which may have either synergistic effects or antagonistic 
effects that could critically affect the success of the 
experimental approaches. Chemotherapy is the most 
well-known treatment for most solid and haematological 
malignancies. However, in some tumourigenesis it 
still harbours either acquired or inherent mechanisms 
for resistance due to miRNAs regulation of multiple 
biological functions and it seems plausible that miRNA 
expression may guide the drug response. These statements 
have been reviewed by Zenz et al. (2009) who found 
that the low expression of miR-34a in CLL is associated 
with p53 inactivation due to chemotherapy-refractory 
disease, which impaired the DNA damage response and 
apoptosis resistance irrespective of TP53 mutation or 
17p deletion. Hence, miR-34a is shown to have a role in 
chemotherapy resistance and thus may serve as a marker 
for poor prognosis for CLL. miRNAs, as circulating 
biomarkers, as well as a non-invasive measurement of 
miRNA expression, is an emerging field that is of great 
interest to both investigators and clinicians. The detection 
of circulating miRNAs has been depicted recently in 
several malignancies including colorectal, lung, breast, 
and ovarian cancer (Hu et al., 2010; Liu et al., 2011). 
In addition, Mitchell and Tewari (2010) identified that 
circulating miRNA in serum in stable form, may circulate 
within exosomes and microvesicles with the potential 
for cell-cell communication; however, the origin for 
circulating miRNAs remains unclear. However, more 
studies are still ongoing to determine whether circulating 
miRNAs may be used as surrogate markers for disease 
activity or response to therapy.
Conclusions
In conclusion, understanding and research are required 
since only one-third of the human genes are predicted 
to be directly targeted by miRNAs. In addition, there 
is still a lot to be discovered when it comes to miRNAs 
and their regulation of the human genome in clarifying 
complex network interactions between miRNAs, other 
classes of ncRNAs, and protein-coding genes and their 
involvement in the development of diseases, especially 
cancer. Concisely, therapeutics can take advantage of this 
new knowledge as well as diagnostics and prognostics, 
and clinical applications exploiting our understanding 
of miRNA function will be the next great challenge in 
cancer research.
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